Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2002, Pages 501-507

  Knoester, P D ^a,d   Jonker, D M ^b   Van Der Hoeven, R T M ^a   Vermeij, T A C ^c   Edelbroek, P M ^c   Brekelmans, G J ^c   De Haan, G J ^c  

^a Stichting Apotheek der Haarlemse Ziekenhuizen   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Formulation; Intranasal; Intravenous; Midazolam; Modelling; Pharmacokinetics pharmacodynamics; PK PD

Indexed keywords

1 HYDROXYMIDAZOLAM; DRUG METABOLITE; MIDAZOLAM; UNCLASSIFIED DRUG; 1-HYDROXYMETHYLMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; ANXIOLYTIC AGENT; DRUG DERIVATIVE;

ADULT; ARTICLE; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG UPTAKE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; HALF LIFE TIME; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NOSE MUCOSA;

ADMINISTRATION, INTRANASAL; ADULT; ANTI-ANXIETY AGENTS, BENZODIAZEPINE; BIOLOGICAL AVAILABILITY; COMPARATIVE STUDY; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGE; MODELS, BIOLOGICAL; NASAL MUCOSA; ANTI-ANXIETY AGENTS; HUMANS; MIDDLE AGED;

EID: 0035999640     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01588.x     Document Type: Article

References (20)

1. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study
2. Buccal midazolam and rectal diazepam for the treatment of prolonged seizures in childhood and adolescence: A randomised trial
3. Pharmacokinetics of midazolam and α-hydroxy-midazolam following rectal and intravenous administration
4. The use of clobazam, midazolam and nitrazepam in epilepsy
5. Nasal rather than rectal benzodiazepines in the management of acute seizures?
6. Intranasal midazolam in patients with status epilepticus
7. Midazolam via the intranasal route: An effective rescue medication for severe epilepsy in adults with a learning disability
8. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?
9. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers
10. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration
11. Complications of intranasal midazolam
12. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
13. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and α-OH-midazolam
14. Dose dependent pharmacokinetics of midazolam
15. Pharmacokinetics and bioavailibility of midazolam in man
16. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients
17. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and EEG effects of phenytoin in rats
18. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration
19. Pharmacokinetic optimisation of benzodiazepine therapy for acute seizures